Recent ELEV News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2024 12:45:20 PM
- Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements • PR Newswire (US) • 11/06/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2024 12:00:40 PM
- Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 • PR Newswire (US) • 09/23/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 08:15:12 PM
- Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/03/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 08:15:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 11:45:51 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 11:30:28 AM
- Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements • PR Newswire (US) • 08/06/2024 11:10:00 AM
- Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2 • PR Newswire (US) • 08/06/2024 11:00:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/15/2024 05:17:58 PM
- Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer • PR Newswire (US) • 06/27/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 08:30:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 08:28:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:15:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 08:10:19 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/10/2024 04:15:22 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/09/2024 08:39:05 PM
- Elevation Oncology to Present at the Citizens JMP Life Sciences Conference • PR Newswire (US) • 05/07/2024 11:30:00 AM
- Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements • PR Newswire (US) • 05/02/2024 11:30:00 AM
- Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 • PR Newswire (US) • 04/08/2024 08:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/06/2024 01:14:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 12:45:37 PM
- Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements • PR Newswire (US) • 03/06/2024 12:30:00 PM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM